The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income (loss) | 1,418 | -1,959 | -615 | -2,406 |
| Impairment of goodwill | 0 | 1,280 | - | - |
| Impairment of goodwill, long-lived assets and assets held for sale | - | - | 1,078 | 2,447 |
| Impairment of long-lived assets and assets held for sale | 1,028 | 1,275 | - | - |
| Depreciation and amortization | 1,002 | 1,059 | 1,153 | 1,308 |
| Net change in operating assets and liabilities | 1,366 | 435 | 72 | -1,257 |
| Deferred income taxes net and uncertain tax positions | -671 | -634 | -317 | -1,059 |
| Stock-based compensation | 157 | 123 | 121 | 124 |
| Research and development in process | - | - | 0 | - |
| Net loss (gain) from sale of business and long-lived assets | 0 | 22 | 41 | -10 |
| Other items, net | 81 | 560 | 61 | -91 |
| Net cash provided by (used in) operating activities | 1,649 | 1,247 | 1,368 | 1,590 |
| Beneficial interest collected in exchange for securitized trade receivables | 1,214 | 1,291 | 1,477 | 1,140 |
| Purchases of property, plant and equipment and intangible assets | 501 | 498 | 526 | - |
| Proceeds from sale of business and long lived assets | 34 | 43 | 68 | 68 |
| Purchases of property, plant and equipment | - | - | - | 548 |
| Purchases of investments and other assets | 57 | 71 | 46 | 1 |
| Proceeds from sale of investments | 42 | 40 | 0 | 4 |
| Acquisitions of businesses, net of cash acquired | 0 | 15 | 0 | 7 |
| Other investing activities | -5 | -2 | 5 | 0 |
| Net cash provided by (used in) investing activities | 737 | 792 | 968 | 656 |
| Repayment of senior notes and loans and other long term liabilities | 4,112 | 1,641 | 4,152 | 1,369 |
| Proceeds from senior notes, net of issuance costs | 2,298 | 0 | 2,451 | 0 |
| Proceeds from short term debt | 0 | 0 | 700 | 0 |
| Repayment of short term debt | 0 | 0 | 700 | 0 |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | -38 | -64 | - | - |
| Redemption of convertible debentures | - | - | 0 | 0 |
| Dividends paid to redeemable and non-redeemable non-controlling interests | -340 | -78 | - | - |
| Other financing activities | 41 | -8 | -212 | -118 |
| Net cash provided by (used in) financing activities | -2,151 | -1,791 | -1,913 | -1,487 |
| Translation adjustment on cash, cash equivalents and restricted cash | 21 | -174 | -30 | -123 |
| Net change in cash, cash equivalents and restricted cash | 256 | 74 | 393 | 636 |
| Cash and cash equivalents at beginning of period | 3,300 | 3,227 | 2,834 | 2,198 |
| Cash and cash equivalents at end of period | 3,556 | 3,300 | 3,227 | 2,834 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)